Background/Aims: Although the very idea that the generative disorder in schizophrenia is a disturbance of the self is as old as the schizophrenia concept itself, empirical studies have only recently emerged, documenting that anomalous self-experiences (i.e. self-disorders, SDs) aggregate in schizophrenia spectrum disorders but not in other mental disorders. The aim of this study is to explore potential associations between SDs, neurocognitive performance, rationality and IQ in patients with schizophrenia. Methods: The sample comprises 31 patients diagnosed with schizophrenia (DSM-IV). All patients underwent comprehensive evaluation. SDs were assessed with the Examination of Anomalous Self-Experience scale. Neurocognitive performance was measured with 4 PC-implemented subtests from the Cambridge Neuropsychological Test Automated Battery. Rationality was measured using syllogism tests. The IQ was indexed by a summary score of 4 IST-2000-R computerized subtests. Results: No correlation was found between SDs and neurocognitive performance or between SDs and IQ. SDs were found to correlate with rationality. Neurocognitive performance correlated with rationality, and both correlated with IQ, respectively. Conclusions: The lack of correlation between SDs and neurocognitive performance is consistent with the results from the only previous study exploring this issue, suggesting that SDs depict something essential to schizophrenia, whereas neurocognitive impairment does not. The correlation between SDs and rationality indicates that the syllogism tests reflect something central for schizophrenia, but the result needs further corroboration from larger, empirical studies.

Keywords:
Examination of Anomalous Self-Experience scale, Phenomenology, Psychopathology, Intelligence quotient, Rationality, Self-disorders, Neurocognition
1.
Berze J: Die primäre Insuffizienz der psychischen Aktivität: Ihr Wesen, ihre Erscheinungen und ihre Bedeutung als Grundstörungen der Dementia Praecox und der Hypophrenen überhaupt. Leipzig, Deuticke, 1914.
2.
Blankenburg W: Der Verlust der natürlichen Selbstverständlichkeit. Ein Beitrag zur Psychopathologie symptomarmer Schizophrenien. Stuttgart, Enke, 1971.
3.
Gruhle H: Schizophrene Grundstimmung (Ich-Störung); in Berze J, Gruhle H (eds): Psychologie der Schizophrenie. Berlin, Springer, 1929, pp 86-94.
4.
Jaspers K: General Psychopathology. London, Johns Hopkins University Press, 1963.
5.
Kronfeld A: Über schizophrene Veränderungen des Bewustsseins der Aktivität. Z Ges Neurol Psychiatrie 1922;74:15-68.
6.
Minkowski E: La schizophrénie. Psychopathologie des schizoïdes et des schizophrènes. Paris, Payot, 1927.
7.
Parnas J: The core gestalt of schizophrenia. World Psychiatry 2012;11:67-69.
8.
Schneider K: Clinical Psychopathology. New York, Grune & Stratton, 1959.
9.
Moller P, Husby R: The initial prodrome in schizophrenia: searching for naturalistic core dimensions of experience and behavior. Schizophr Bull 2000;26:217-232.
10.
Parnas J, Jansson L, Sass LA, Handest P: Self-experience in the prodromal phases of schizophrenia: a pilot study of first admissions. Neurol Psychiatry Brain Res 1998;6:107-116.
11.
Parnas J, Moller P, Kircher T, Thalbitzer J, Jansson L, Handest P, Zahavi D: EASE: Examination of Anomalous Self-Experience. Psychopathology 2005;38:236-258.
12.
Henriksen MG, Parnas J: Clinical manifestations of self-disorders and the gestalt of schizophrenia. Schizophr Bull 2012;38:657-660.
13.
Parnas J: A disappearing heritage: the clinical core of schizophrenia. Schizophr Bull 2011;37:1121-1130.
14.
Skodlar B, Henriksen MG, Sass LA, Nelson B, Parnas J: Cognitive-behavioral therapy for schizophrenia: a critical evaluation of its theoretical framework from a clinical-phenomenological perspective. Psychopathology 2013;46:249-265.
15.
Sass LA, Parnas J: Schizophrenia, consciousness, and the self. Schizophr Bull 2003;29:427-444.
16.
Parnas J, Handest P, Jansson L, Saebye D: Anomalous subjective experience among first-admitted schizophrenia spectrum patients: empirical investigation. Psychopathology 2005;38:259-267.
17.
Raballo A, Parnas J: The silent side of the spectrum: schizotypy and the schizotaxic self. Schizophr Bull 2011;37:1017-1026.
18.
Nordgaard J, Parnas J: Self-disorders and the schizophrenia spectrum: a study of 100 first hospital admissions. Schizophr Bull 2014;40:1300-1307.
19.
Haug E, Lien L, Raballo A, Bratlien U, Oie M, Andreassen OA, Melle I, Moller P: Selective aggregation of self-disorders in first-treatment DSM-IV schizophrenia spectrum disorders. J Nerv Ment Dis 2012;200:632-636.
20.
Parnas J, Handest P, Saebye D, Jansson L: Anomalies of subjective experience in schizophrenia and psychotic bipolar illness. Acta Psychiatr Scand 2003;108:126-133.
21.
Koren D, Reznik N, Adres M, Scheyer R, Apter A, Steinberg T, Parnas J: Disturbances of basic self and prodromal symptoms among non-psychotic help-seeking adolescents. Psychol Med 2013;43:1365-1376.
22.
Nelson B, Thompson A, Yung AR: Basic self-disturbance predicts psychosis onset in the ultra high risk for psychosis ‘prodromal' population. Schizophr Bull 2012;38:1277-1287.
23.
Parnas J, Raballo A, Handest P, Jansson L, Vollmer-Larsen A, Saebye D: Self-experience in the early phases of schizophrenia: 5-year follow-up of the Copenhagen Prodromal Study. World Psychiatry 2011;10:200-204.
24.
Parnas J, Henriksen MG: Disordered self in the schizophrenia spectrum: a clinical and research perspective. Harv Rev Psychiatry 2014;22:251-265.
25.
Lepage M, Bodnar M, Bowie CR: Neurocognition: clinical and functional outcomes in schizophrenia. Can J Psychiatry 2014;59:5-12.
26.
Agnew-Blais J, Seidman LJ: Neurocognition in youth and young adults under age 30 at familial risk for schizophrenia: a quantitative and qualitative review. Cogn Neuropsychiatry 2013;18:44-82.
27.
Comparelli A, De Carolis A, Corigliano V, Romano S, Kotzalidis G, Brugnoli R, Tamorri S, Curto M, Tatarelli R, Ferracuti S, Girardi P: Neurocognition, psychopathology, and subjective disturbances in schizophrenia: a comparison between short-term and remitted patients. Compr Psychiatry 2012;53:931-939.
28.
Minor KS, Lysaker PH: Necessary, but not sufficient: links between neurocognition, social cognition, and metacognition in schizophrenia are moderated by disorganized symptoms. Schizophr Res 2014;159:198-204.
29.
Haug E, Oie M, Melle I, Andreassen OA, Raballo A, Bratlien U, Lien L, Moller P: The association between self-disorders and neurocognitive dysfunction in schizophrenia. Schizophr Res 2012;135:79-83.
30.
Stanovich KE: Rationality and the Reflective Mind. New York, Oxford University Press, 2011.
31.
Goel V, Bartolo A, St Clair D, Venneri A: Logical reasoning deficits in schizophrenia. Schizophr Res 2004;66:87-88.
32.
Goel V, Dolan RJ: Explaining modulation of reasoning by belief. Cognition 2003;87:B11-B22.
33.
Mirian D, Heinrichs RW, McDermid Vaz S: Exploring logical reasoning abilities in schizophrenia patients. Schizophr Res 2011;127:178-180.
34.
Owen GS, Cutting J, David AS: Are people with schizophrenia more logical than healthy volunteers? Br J Psychiatry 2007;191:453-454.
35.
Williams EB: Deductive reasoning in schizophrenia. J Abnorm Psychol 1964;69:47-61.
36.
Mujica-Parodi LR, Malaspina D, Sackeim HA: Logical processing, affect, and delusional thought in schizophrenia. Harv Rev Psychiatry 2000;8:73-83.
37.
Speechley WJ, Murray CB, McKay RM, Munz MT, Ngan ET: A failure of conflict to modulate dual-stream processing may underlie the formation and maintenance of delusions. Eur Psychiatry 2010;25:80-86.
38.
First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV TR Axis I Disorders (1/2007 revision). New York, Biometrics Research Department, New York State Psychiatric Institute, 2007.
39.
McGuffin P, Farmer A, Harvey I: A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991;48:764-770.
40.
Kety SS, Rosenthal D, Wender PH, Schulsinger F: The types and prevalence of mental illness in the biological and adoptive families of adopted schizophrenics; in Rosenthal D, Kety SS (eds): The Transmission of Schizophrenia. Oxford, Pergamon Press, 1968.
41.
Kety SS, Rosenthal D, Wender PH, Schulsinger F, Jacobsen B: Mental illness in the biological and adoptive families of adopted individuals who have become schizophrenic: a preliminary report based on psychiatric interviews; in Fieve RR, Rosenthal D, Brill H (eds): Genetic Research in Psychiatry. Baltimore, Johns Hopkins University Press, 1975.
42.
Matthysse S, Holzman PS, Gusella JF, Levy DL, Harte CB, Jorgensen A, Moller L, Parnas J: Linkage of eye movement dysfunction to chromosome 6p in schizophrenia: additional evidence. Am J Med Genet B Neuropsychiatr Genet 2004;128B:30-36.
43.
Endicott J, Spitzer RL: A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978;35:837-844.
44.
Gross G, Huber G, Klosterkötter J, Linz M: Bonner Skala für die Beurteilung von Basissymptomen. Berlin, Springer, 1987.
45.
Jakobsen KD, Frederiksen JN, Hansen T, Jansson LB, Parnas J, Werge T: Reliability of clinical ICD-10 schizophrenia diagnoses. Nordic J Psychiatry 2005;59:209-212.
46.
Jakobsen KD, Frederiksen JN, Parnas J, Werge T: Diagnostic agreement of schizophrenia spectrum disorders among chronic patients with functional psychoses. Psychopathology 2006;39:269-276.
47.
Maggini C, Raballo A: Subjective experience of schizotropic vulnerability in siblings of schizophrenics. Psychopathology 2004;37:23-28.
48.
Moller P, Haug E, Raballo A, Parnas J, Melle I: Examination of anomalous self-experience in first-episode psychosis: interrater reliability. Psychopathology 2011;44:386-390.
49.
Skodlar B, Tomori M, Parnas J: Subjective experience and suicidal ideation in schizophrenia. Compr Psychiatry 2008;49:482-488.
50.
Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, Crockford HA, Crooks M, Hill K, Levy R: Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology 1993;110:395-401.
51.
Riekkinen M, Laakso MP, Jakala P: Clonidine impairs sustained attention and memory in Alzheimer's disease. Neuroscience 1999;92:975-982.
52.
Morris RG, Downes JJ, Sahakian BJ, Evenden JL, Heald A, Robbins TW: Planning and spatial working memory in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:757-766.
53.
Owen AM, Iddon JL, Hodges JR, Summers BA, Robbins TW: Spatial and non-spatial working memory at different stages of Parkinson's disease. Neuropsychologia 1997;35:519-532.
54.
Downes JJ, Roberts AC, Sahakian BJ, Evenden JL, Morris RG, Robbins TW: Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychologia 1989;27:1329-1343.
55.
Coull JT, Middleton HC, Robbins TW, Sahakian BJ: Contrasting effects of clonidine and diazepam on tests of working memory and planning. Psychopharmacology 1995;120:311-321.
56.
Elliott R, Sahakian BJ, Herrod JJ, Robbins TW, Paykel ES: Abnormal response to negative feedback in unipolar depression: evidence for a diagnosis specific impairment. J Neurol Neurosurg Psychiatry 1997;63:74-82.
57.
Von Liepmann D, Beauducek B, Brocke B, Amthauer R: Intelligenz-Struktur-Test 2000 R (I-S-T 2000 R), ed 2, erweit überarb Aufl. Göttingen, Hogrefe, 2001.
58.
Schultze-Lutter F, Ruhrmann S, Picker H, von Reventlow HG, Daumann B, Brockhaus-Dumke A, Klosterkötter J, Pukrop R: Relationship between subjective and objective cognitive function in the early and late prodrome. Br J Psychiatry Suppl 2007;51:s43-s51.
59.
Zanello A, Huguelet P: Relationship between subjective cognitive symptoms and frontal executive abilities in chronic schizophrenic outpatients. Psychopathology 2001;34:153-158.
60.
Cuesta MJ, Peralta V, Juan JA: Abnormal subjective experiences in schizophrenia: its relationships with neuropsychological disturbances and frontal signs. Eur Arch Psychiatry Clin Neurosci 1996;246:101-105.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.